Cocoa has long carried a health halo, often with more enthusiasm than evidence. Now, one of the largest and most rigorous trials of its kind has given that discussion a sharper scientific edge.

A cocoa flavanol supplement did not significantly reduce the trial’s main measure of overall cardiovascular events, yet it was linked with a notable reduction in cardiovascular deaths. That finding is not a green light to eat more chocolate. It is a signal. A serious one, according to researchers, though still one that needs confirmation.

The results come from the COcoa Supplement and Multivitamin Outcomes Study, known as COSMOS, a large randomised, placebo-controlled trial that examined whether a cocoa extract supplement or a daily multivitamin could help prevent New 2026 Dietary Guidance to Improve Cardiovascular Health and Protect Your Heartcardiovascular disease or cancer. The findings were published in The American Journal of Clinical Nutrition.

More than 21,000 adults took part. Participants were assigned to receive daily capsules containing 500 mg of cocoa flavanols, a daily multivitamin, both products, or placebo. The study was led by preventive medicine researchers at Brigham and Women’s Hospital.

The headline result is careful. Cocoa flavanols reduced total cardiovascular events by 10%, yet that reduction did not reach statistical significance. In clinical research, that matters. A result that is not statistically significant may reflect a real effect, random variation, or a mixture of both. Scientists do not treat it as proof.

Still, the secondary findings drew attention. Participants who received the cocoa flavanol supplement had a 27% lower rate of death from cardiovascular disease compared with those who did not receive it. Cardiovascular death was a pre-specified secondary endpoint, meaning researchers had planned to examine it before the results were known. That makes the finding more meaningful than an unexpected pattern found after searching through data.

The signal looked stronger among participants who took the study pills regularly. In that adherence analysis, cocoa flavanols were associated with a 15% reduction in total cardiovascular events and a 39% reduction in cardiovascular death. A separate composite measure of major cardiovascular events, including heart attacks, strokes, and cardiovascular deaths, was also significantly reduced, although it was not the main focus of the trial.

These results are promising. They are not definitive.

The researchers were careful to stress that point. Experts said the full pattern of primary and secondary cardiovascular findings suggested that cocoa flavanols might reduce important cardiovascular events, including deaths from cardiovascular disease. They also said the evidence warranted further investigation. That caution is important, particularly because nutrition research is often oversimplified once it reaches the public.

This was not a chocolate trial. That distinction is essential. The trial tested a purified cocoa extract supplement providing a defined dose of cocoa flavanols. Chocolate contains cocoa compounds, yet it also contains calories, sugar, saturated fat, and other ingredients. A person could not realistically consume the same amount of cocoa flavanols from ordinary chocolate without adding substantial extra energy, fat, and sugar to the diet. Dark chocolate may contain more cocoa compounds than milk chocolate, but the flavanol content varies widely by product, processing method, and serving size.

Flavanols are plant-based compounds found in cocoa, tea, grapes, berries, apples, and other foods. They are part of a broader family of bioactive compounds studied for possible effects on blood vessels, inflammation, oxidative stress, and cardiovascular function. Earlier smaller trials had suggested that cocoa flavanols may improve blood pressure and blood vessel dilation. Those studies were typically shorter. Many focused on intermediate measures rather than hard clinical outcomes such as heart attacks, strokes, or death.

COSMOS was designed to ask a larger, longer, more practical question: could daily supplementation reduce real cardiovascular events over time?

The primary cardiovascular outcome for the cocoa flavanol arm was broad. It included heart attacks, stroke, coronary revascularisation, cardiovascular death, carotid artery disease, peripheral artery surgery, and unstable angina. This type of composite outcome helps researchers capture enough events to assess whether a treatment may be having an effect. It can also make interpretation more complicated, because not every component carries the same clinical weight.

In COSMOS, the broad primary cardiovascular outcome moved in a favourable direction, but not enough to be considered statistically significant. The more striking result came from cardiovascular death. That is a grave endpoint. It is also one that patients, clinicians, and public health experts care about deeply.

The findings on adherence deserve attention, though they should be read with care. Trials often analyse results based on intention to treat, meaning participants are evaluated according to the group they were assigned to, regardless of how faithfully they took the pills. That preserves the benefits of randomisation. Adherence analyses can show what happened among people who actually took the intervention more consistently, yet they can also introduce bias. People who take pills regularly may differ from those who do not in ways that affect health outcomes.

Even so, the adherence results supported the same general pattern. Cocoa flavanols may have cardiovascular benefits. The message is intriguing, not settled.

The multivitamin results were less encouraging for cardiovascular prevention. A daily multivitamin did not significantly reduce total cardiovascular events or individual cardiovascular outcomes. It improved levels of several nutritional biomarkers, according to the study reports, but that did not translate into a clear reduction in cardiovascular disease during the trial period.

Cancer prevention was also examined. Neither cocoa flavanols nor the multivitamin had a significant effect on total invasive cancer during the study. Researchers noted that the trial lasted about 3.6 years, which may have been too short to detect meaningful effects on cancer risk. Cancer often develops over many years. A longer follow-up may provide more information about cancer, death, cognitive decline, falls, eye disease, and other ageing-related outcomes being studied through COSMOS.

Safety is another important part of the story. The trial reported no major safety concerns for either cocoa flavanols or the multivitamin. That does not mean every supplement is risk-free for every person. People with medical conditions, those taking multiple medicines, and anyone considering a new daily supplement should discuss it with a healthcare professional. Supplements can interact with medicines. They can also vary in quality, dose, formulation, and oversight.

The public health challenge is translation. What should a reader do with this information today?

The clearest advice remains familiar. Eat a balanced diet rich in plant-based foods, including fruits, vegetables, whole grains, nuts, seeds, legumes, and flavanol-containing foods such as tea, berries, grapes, apples, and cocoa products with minimal added sugar. Avoid treating chocolate as medicine. Do not assume more is better. A supplement tested in a trial is not the same as a confectionery product from a supermarket shelf.

Cardiovascular disease remains a leading cause of death worldwide. Even modest reductions in cardiovascular risk can matter at population level if they are real, safe, affordable, and widely applicable.

Yet prevention is rarely built on a single compound. Blood pressure control, cholesterol management, smoking cessation, physical activity, diabetes care, sleep, weight management, and dietary quality remain central. A cocoa flavanol capsule, if eventually confirmed as beneficial, would be an addition to prevention, not a replacement for proven measures.

The trial also highlights how modern nutrition science is changing. For decades, public conversations about food often revolved around broad categories such as fat, carbohydrates, calories, vitamins.

Today, researchers are also examining bioactive compounds in foods, including flavanols, polyphenols, and other plant chemicals that may affect human physiology. These compounds are not nutrients in the classic deficiency-disease sense. Still, they may influence health through vascular, metabolic, or inflammatory pathways.

Future trials will need to confirm whether cocoa flavanols truly reduce cardiovascular events, identify which groups may benefit most, clarify the necessary dose, assess long-term safety, and determine whether benefits depend on baseline diet or cardiovascular risk. It will also be important to understand whether similar effects can be achieved through ordinary foods, targeted supplements, or both.

For now, the study offers a refined message. Cocoa flavanols may be more than a nutrition curiosity. They may have measurable cardiovascular effects. The evidence is strong enough to justify further research, yet not strong enough to support broad clinical recommendations for supplementation.

That nuance may be less catchy than “chocolate protects the heart”. It is far more accurate.

The news, then, is not that chocolate has become a health food. It has not. The news is that a carefully tested cocoa extract, rich in flavanols, produced encouraging cardiovascular signals in a large clinical trial. In particular, it was associated with fewer deaths from cardiovascular disease. That is worth watching closely.

Science often advances this way. Not with instant certainty. With patterns, caution, replication, and time.